In an adult male taking lithium 1200 mg daily, is a serum lithium level of 1.0 mmol/L (or mEq/L) within the therapeutic range?

Yes, a serum lithium level of 1.0 mmol/L is within normal limits for an adult male on maintenance therapy, though it sits at the upper end of the currently recommended therapeutic range.

Therapeutic Range Context

For adult maintenance therapy, the optimal serum lithium level is 0.6-1.0 mmol/L, with most current evidence supporting 0.6-0.8 mmol/L as the preferred target range 1. Your patient's level of 1.0 mmol/L is technically within the acceptable therapeutic window but warrants careful clinical assessment.

Evidence-Based Therapeutic Targets

The FDA emphasizes that lithium toxicity is closely related to serum levels and can occur at doses close to therapeutic levels 2. This narrow therapeutic index necessitates precise monitoring.

Key therapeutic range data:

• Standard maintenance range: 0.6-0.8 mmol/L is now generally accepted as optimal 1
• Upper acceptable limit: Up to 1.0 mmol/L remains within therapeutic range 1
• Historical vs. current practice: Older guidelines recommended 0.8-1.2 mmol/L, but a landmark 1989 study demonstrated that 0.8-1.0 mmol/L provides superior efficacy compared to lower ranges (0.4-0.6 mmol/L), with relapse risk 2.6 times higher in the low-dose group 3

Clinical Decision Algorithm

At a level of 1.0 mmol/L, you should:

1. Assess for early toxicity signs: tremor (especially fine hand tremor), diarrhea, urinary frequency, weight gain, metallic taste, cognitive slowing 1, 3

2. Evaluate patient-specific risk factors:

   • Age (older adults require lower targets)
   • Renal function (check creatinine, eGFR)
   • Concomitant medications (diuretics, ACE inhibitors, NSAIDs increase toxicity risk) 4
   • Hydration status

3. Consider dose adjustment based on clinical picture:

   • If tolerating well with no side effects → maintain current dose
   • If experiencing side effects → reduce to target 0.6-0.8 mmol/L
   • If age >60 years → strongly consider reduction to 0.4-0.7 mmol/L 4, 5

Important Caveats

Age considerations: If this patient is older (≥60 years), a level of 1.0 mmol/L is likely too high. Recent evidence from the ISBD task force recommends 0.4-0.8 mmol/L for ages 60-79 and 0.4-0.7 mmol/L for ages ≥80 years, as age-related reduction in renal clearance increases toxicity risk 4, 5.

Timing matters: Ensure the blood draw occurred 12 hours post-dose. Non-standardized timing can lead to falsely elevated or reduced readings 6. If timing was off, use the eLi12 equation to estimate the true 12-hour level.

Side effect trade-off: While 0.8-1.0 mmol/L provides better relapse prevention than lower ranges, it comes with increased side effects including tremor, diarrhea, and urinary frequency 3. The clinical decision should balance efficacy against tolerability.

Monitoring Recommendations

• Recheck level in 1-2 weeks if any dose adjustment is made
• Monitor renal function (creatinine, eGFR) every 6-12 months 7
• Watch for progressive or sudden changes in renal function, even within normal range, as this indicates need for treatment reevaluation 2
• Assess thyroid function periodically
• Educate patient on signs of toxicity and importance of hydration

Bottom line: 1.0 mmol/L is acceptable but represents the ceiling of the therapeutic range. Clinical context—particularly age, tolerability, and renal function—should guide whether to maintain this level or reduce toward the 0.6-0.8 mmol/L target that balances efficacy with safety.